United Capital Financial Advisors LLC Sells 1,597 Shares of Grifols, S.A. (NASDAQ:GRFS)

United Capital Financial Advisors LLC lessened its holdings in Grifols, S.A. (NASDAQ:GRFS) by 13.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 10,657 shares of the biotechnology company’s stock after selling 1,597 shares during the period. United Capital Financial Advisors LLC’s holdings in Grifols were worth $79,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in GRFS. HighTower Advisors LLC increased its stake in Grifols by 12.5% in the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,546 shares during the period. Stifel Financial Corp acquired a new position in shares of Grifols in the 3rd quarter worth approximately $1,043,000. Jane Street Group LLC acquired a new stake in Grifols in the 3rd quarter valued at $363,000. Barclays PLC grew its position in Grifols by 381.2% in the third quarter. Barclays PLC now owns 592,552 shares of the biotechnology company’s stock valued at $5,261,000 after acquiring an additional 469,401 shares during the period. Finally, Geode Capital Management LLC raised its stake in Grifols by 56.1% during the third quarter. Geode Capital Management LLC now owns 110,532 shares of the biotechnology company’s stock worth $982,000 after acquiring an additional 39,733 shares in the last quarter.

Grifols Trading Up 2.4 %

GRFS stock opened at $7.18 on Wednesday. The business has a fifty day moving average price of $7.48 and a 200 day moving average price of $7.79. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The stock has a market capitalization of $4.94 billion, a price-to-earnings ratio of 6.14 and a beta of 0.41.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley started coverage on shares of Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.